A Retrospective Observational Study to Assess Prescription Pattern in Patients with Type B Aortic Dissection and Treatment Outcome
Table 5
Treatment strategy of antihypertensive drugs and event rate.
Treatment strategy
Number of patients
%
Event rate, (%)
Primary endpoints
Hosp.
Death
Surgery
None
11
10.4%
5 (45.5%)
3 (27.3%)
2 (18.2%)
1 (9.1%)
Monotherapy
10
9.4%
2 (20.0%)
1 (10.0%)
1 (10.0%)
0 (0%)
-blocker
5
50.0%
0 (0%)
0 (0%)
0 (0%)
0 (0%)
CCB
1
10.0%
0 (0%)
0 (0%)
0 (0%)
0 (0%)
Others
4
40.0%
1 (25.0%)
1 (25.0%)
1 (25.0%)
0 (0%)
Dual therapy
31
29.3%
8 (25.8%)
6 (19.4%)
3 (9.7%)
4 (12.9%)
-blocker + CCB
18
58.1%
3 (16.7%)
3 (16.7%)
0 (0%)
2 (11.1%)
-blocker + Others
5
16.1%
2 (40.0%)
2 (40.0%)
2 (40.0%)
2 (40.0%)
CCB + RAS
3
9.7%
0 (0%)
0 (0%)
0 (0%)
0 (0%)
CCB + Others
4
12.9%
1 (25.0%)
1 (25.0%)
1 (25.0%)
0 (0%)
RAS + Others
1
3.2%
0 (0%)
0 (0%)
0 (0%)
0 (0%)
Triple therapy
42
39.6%
12 (28.6%)
9 (21.4%)
4 (9.5%)
3 (7.1%)
-blocker + CCB + RAS
14
33.3%
3 (21.4%)
3 (21.4%)
0 (0%)
3 (21.4%)
-blocker + CCB + Others
20
47.6%
5 (25.0%)
5 (25.0%)
1 (5.0%)
0 (0%)
-blocker + RAS + Others
4
9.5%
1 (25.0%)
1 (25.0%)
2 (50.0%)
0 (0%)
CCB + RAS + Others
4
9.5%
0 (0%)
0 (0%)
1 (25.0%)
0 (0%)
Quadruple therapy
12
11.3%
3 (25.0%)
1 (8.3%)
2 (16.7%)
1 (8.3%)
CCB: calcium channel blockers; RAS: drugs acting on the rennin-angiotensin system. #Antihypertensive drugs divided into -blockers, drugs acting on the rennin-angiotensin system (including angiotensin converting enzyme inhibitors, angiotensin receptor blocker, and direct renin inhibitors), calcium channel blockers, and all other antihypertensive classes (including diuretics, -blockers, vasodilators, and central 2 agonists). All-cause mortality and admission to hospital because of aortic dissection (primary endpoint). Hospitalization associated with aortic dissection. All-cause mortality. £ Referred to surgery repair.
